Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as
monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be
obtained from the current phase III trials . The study aims to enroll fourteen patients
(seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR
in the morning under fasted conditions and PK samples will be taken up to 36h.